Documentation Expectations for Advanced Natural-Blue Inputs

The gap between a technically capable phycocyanin and a procurement-ready one is, in most regulated-market contexts, almost entirely a documentation gap. A supplier can produce material with a purity ratio above 4.0, acceptable endotoxin readings, and low heavy-metal burden — and still fail qualification at a pharmaceutical or diagnostics procurement desk because the accompanying paperwork is structurally incomplete, inconsistently formatted, or simply absent for the fields that matter. For buyers sourcing advanced natural-blue inputs into fluorescence-linked immunoassay workflows, in vitro diagnostic reagent formulations, or investigational compound libraries, the documentation set is the product in a meaningful regulatory sense.

This is particularly true for phycocyanin entering supply chains governed by the EU In Vitro Diagnostic Regulation (IVDR 2017/746), FDA's quality system expectations for biological colorants and reagent materials, Japan's PMDA guidance on imported biological inputs, or China's NMPA frameworks for diagnostic raw materials. Each of these regulatory environments has evolved to expect documentation that is traceable, reproducible, and format-stable across lots. What follows is a structured walkthrough of what that documentation set looks like for E40-grade phycocyanin — material with a purity ratio (A620/A280) at or above 4.0 — and how SPIRUVA's documentation framework is being designed ahead of the July 2027 commercial launch.

---

Technical Data Sheet: The Foundational Reference Document

The Technical Data Sheet (TDS) is not a marketing brochure. For advanced applications, it functions as the primary reference against which a buyer's internal quality team will assess fit-for-purpose before a sample is even requested. A credible TDS for E40-grade phycocyanin should carry, at minimum: the product name and internal catalogue identifier, the botanical source (Arthrospira platensis or equivalent with strain-level notation where relevant), the declared purity ratio range with the measurement methodology cited, the physical form (lyophilised powder, solution concentrate), nominal moisture content, solubility specifications, and storage conditions. It should also carry a clear statement of intended use tier — distinguishing between food-grade, cosmetic-grade, research-grade, and pharmaceutical/diagnostic-grade — because conflating these in a single TDS is a qualification red flag.

SPIRUVA's TDS architecture is being structured at the product-grade level, not the lot level. This means buyers at the pre-qualification stage will receive a document that accurately reflects the specification envelope against which each Certificate of Analysis is measured — rather than a retroactively written summary of what was produced.

---

Certificate of Analysis: Non-Negotiable Fields

The Certificate of Analysis (CoA) is a lot-specific document. Its credibility rests on how directly its test results map to a disclosed method, and how clearly it identifies the batch to which it belongs. For E40-grade material, procurement teams in regulated markets expect the following fields without exception:

• Lot number and production date, with an unambiguous link to the biomass harvest batch
• Purity ratio (A620/A280) — the defining specification for this tier, with the instrument used, path length, and solvent system noted
• Phycocyanin content (%) by weight, calculated against a declared extinction coefficient
• Moisture content — typically by Karl Fischer or loss-on-drying, with the method cited
• Endotoxin / LAL result in EU/mg or EU/mL, with the test format (gel-clot, turbidimetric, chromogenic) specified
• Bioburden — total aerobic microbial count and total yeast/mold count
• Heavy metals panel — at minimum Pb, Cd, As, Hg, with method (ICP-MS or ICP-OES cited)
• Appearance — color, physical form, and any noted visual deviations
• Retest or expiry date
• Authorized signatory with title

The absence of any of these fields — or their replacement with qualitative statements such as 'conforms' without a numerical value — will typically trigger a supplier qualification failure at EU IVDR-aligned procurement desks. SPIRUVA's CoA template is being designed to meet this field set as a baseline, with provision for customer-requested additional fields built into the format architecture.

---

Method of Analysis: Transparency on Instrumentation and Standards

A Method of Analysis (MoA) document answers the question that every quality-assurance chemist asks when reviewing a CoA: how was this number generated? For phycocyanin at E40 purity, the MoA is particularly important because spectrophotometric purity measurements are sensitive to instrument calibration, cuvette path length, dilution protocols, and baseline correction methodology. A CoA that reports a purity ratio of 4.2 without a corresponding MoA is not independently verifiable and will not pass a technology transfer audit.

Instrument and Reference Standard Disclosure

SPIRUVA's MoA framework is being built to include, for each reported parameter: the analytical technique (UV-Vis spectrophotometry, ICP-MS, Karl Fischer titration, LAL, plate-count microbiological methods), the instrument model and calibration traceability, the reference standards used (with CAS numbers or compendial citation where applicable), the sample preparation protocol, and the calculation methodology. For spectrophotometric purity, this includes the specific extinction coefficients applied and their published source.

This level of method transparency is a prerequisite for buyers conducting method validation in their own facilities — a standard step for any diagnostic manufacturer incorporating a new raw material into a registered product.

---

Traceability File: From Biomass Lot to Final Lyophilised Batch

Traceability is where many otherwise capable phycocyanin suppliers expose structural weakness. A traceability file is the documentary chain connecting an identified biomass harvest lot through each processing step — extraction, clarification, precipitation or ultrafiltration, lyophilisation — to the final labeled batch. For regulated applications, this chain needs to be reconstructible from records, not reconstructed from memory.

For SPIRUVA's E40-grade material, the traceability architecture being developed by the Carbofixers technical team includes: biomass lot identification linked to cultivation date, tank ID, and harvest conditions; in-process quality checkpoints with pass/fail criteria at each stage; yield records that allow batch reconciliation; and lyophilisation cycle records including shelf temperature profiles and residual moisture outcomes. The purpose of this architecture is to allow a buyer's quality auditor to trace any reported anomaly in a finished-goods batch back to a specific production event — a requirement that becomes mandatory, rather than optional, for suppliers seeking inclusion in IVDR-registered diagnostic supply chains.

---

Residual and Contaminant Panels: Heavy Metals, Host-Cell, Microbiological

For phycocyanin entering diagnostic or pharmaceutical formulations, the contaminant panel is one of the most scrutinized sections of the documentation set. Heavy metal testing should cover the four elements required by ICH Q3D-aligned frameworks: lead, cadmium, arsenic, and mercury. For materials with defined oral or parenteral exposure pathways, the full elemental impurity panel may be required, and SPIRUVA's testing design is being structured to accommodate that expansion.

Host-cell protein and host-cell DNA residual testing — terminology borrowed from biologic manufacturing — has begun to appear in advanced phycocyanin specifications, particularly for buyers developing fluorescent-conjugate reagents where background protein contamination affects signal-to-noise performance. This is an emerging documentation expectation rather than a universally mandated one, but suppliers who cannot address it in a technical conversation will find themselves excluded from advanced diagnostics qualification discussions.

Microbiological panels for E40-grade material should include total aerobic count, total combined yeast and mold count, Salmonella absence, E. coli absence, and — for any material with endotoxin relevance — a validated LAL result. These tests should be conducted per USP, EP, or JP compendial method, with the relevant pharmacopoeial edition cited.

---

Stability and Shelf-Life Data

Stability data for phycocyanin is complicated by the molecule's known photosensitivity and thermal lability. For E40-grade lyophilised material, buyers expect real-time stability data conducted under defined ICH-aligned storage conditions, with purity ratio, color value, and moisture content as primary stability-indicating parameters. Accelerated stability studies are acceptable as supporting data but will not replace real-time data for formal qualification purposes.

SPIRUVA's stability program is being initiated at production scale ahead of the July 2027 launch, with study design aligned to ICH Q1A(R2) principles as the structural reference. Shelf-life claims on CoAs issued at launch will be supported by data packages available for technical review upon request.

---

Regulatory Dossier Components and Drug Master File-Style References

For phycocyanin used in pharmaceutical or diagnostic applications where the finished product is itself registered or notified, buyers may require access to a Drug Master File (DMF)-style reference package or equivalent. In the EU context, this may take the form of a European Drug Master File or a declaration of conformity with IVDR Annex I requirements. In the US context, an FDA Type II DMF provides a confidential technical disclosure that allows a buyer's regulatory submission to reference supplier quality information without its public disclosure.

SPIRUVA's dossier architecture is being structured to support this pattern. This means documentation is being organized from the outset in a manner consistent with CTD (Common Technical Document) module structures, so that components can be extracted and formatted for regulatory submissions without requiring retroactive reconstruction. Buyers with specific dossier requirements for their target markets — FDA, EMA, PMDA, or NMPA — are encouraged to initiate technical conversations now, so that documentation scope can be aligned against the July 2027 production timeline.

---

GMP-Adjacent Practices and Change Control

For a non-medicinal raw material, full GMP certification is not always the relevant standard. However, buyers in regulated markets have increasingly adopted the concept of 'GMP-adjacent' expectations: practices that mirror GMP discipline in personnel training records, equipment calibration logs, environmental monitoring, and batch record retention, without requiring the full infrastructure of a licensed pharmaceutical manufacturer.

SPIRUVA's quality management system is being developed against this standard. This includes: written SOPs for all production-critical steps, training records linked to personnel and procedure version, calibration and maintenance logs for analytical instruments, and batch record formats that support retrospective audit.

Change Control and Notification Protocols

Change control is the area most commonly neglected in supplier qualification discussions, and the one that causes the most downstream disruption. For regulated-market buyers, a supplier change — to raw material source, process step, instrument, or testing laboratory — that is not proactively communicated can trigger re-qualification obligations or, in worst cases, product recall investigations. SPIRUVA's change-control protocol is being designed to include a formal notification obligation to allocated buyers for any change that falls within defined category thresholds, with a minimum lead time of sixty days for significant changes. This protocol will be disclosed as part of the supply agreement documentation, not left as an informal commitment.

---

The documentation expectations described here are not aspirational standards reserved for large pharmaceutical manufacturers — they are the baseline that procurement teams at diagnostics developers, clinical reagent formulators, and regulated research institutions apply when evaluating a new phycocyanin input. SPIRUVA's decision to design against these expectations as a launch-stage architecture, rather than addressing them reactively post-launch, reflects a judgment that the E40-grade market is won or lost at the documentation desk as much as in the fermentation vessel. Technical review conversations with prospective allocated buyers are open now, ahead of the July 2027 production start.

→ Discuss your E40 evaluation ahead of July 2027 readiness